The cell surface is home to these CD95 receptors. When activated, they set off a chain of chemical reactions that lead to the death of cells.
They are essential for preserving cellular equilibrium, but until recently, scientists had not fully investigated their potential. Therapeutic resistance, which occurs.
When cells become resistant to standard therapies, is one of the main obstacles in the battle against cancer. Currently, radiation, chemotherapy, and surgery are the standard therapies.
Furthermore, immune-based treatments, such CAR (chimeric antigen receptor) T-cell therapy, have been used to combat this illness; however, their efficacy is restricted to certain cancer kinds.
“Long-term remission remains the biggest challenge for CAR T-cell therapies, despite their decent success in liquid tumors, such as leukemia spectrum cancers,” Tushir-Singh told Fox News.
In addition to curing leukemia, the research found that there are now “hopes and potential solutions to transform the meager success of CAR-T therapies into potentially successful [therapies for] solid tumors.”
